Federal Circuit: Reverses Motion to Dismiss—Generic Manufacturer’s Label Combined with its Expansive Public Statements Plausibly Induced Infringement

June 25, 2024

Reading Time : 2 min

The Federal Circuit reversed a decision from the District of Delaware dismissing a case for failing to plead induced infringement because the totality of the evidence raised fact questions that could not be resolved on a motion to dismiss. The Federal Circuit expressed doubts about whether appellee’s FDA-approved label alone, which carved out the claimed indication, was sufficient to actively induce. But the court held appellee’s label combined with its public statements that broadly refer to its drug as a generic version and provide usage and sales data for carved out indications, created a plausible basis for pleading induced infringement.

This appeal stems from an infringement suit brought in the District of Delaware for infringement of claims for reducing cardiovascular events brought against a generic manufacturer of appellant’s drug, Vascepa. In 2012, Vascepa was approved for the treatment of severe hypertriglyceridemia (SH). When Vascepa was first approved, its label included an express “limitation of use,” stating its effect on cardiovascular mortality and morbidity was not yet determined. In 2019, the FDA approved Vascepa to reduce cardiovascular risk. As a result of this approval, the limitation of use was removed from the Vascepa label. 

Appellee in this case sought a label for the SH indication, and initially included the limitation of use language in its label. After Vascepa was approved to reduce cardiovascular risk, appellee revised its ANDA to indicate that it was seeking a “skinny label” for only the SH indication and would carve out the cardiovascular risk indication. Appellee also removed the limitation of use language from its proposed label.  Around the time appellee received approval for its generic Vascepa, it issued several press releases touting its drug as generic Vascepa without limitation and citing to overall U.S. sales of Vascepa, including sales attributable to the cardiovascular risk indication. Appellee also established a website that included, in small letters, the statement that its generic was approved for fewer than all approved indications for Vascepa.

The district court dismissed appellants complaint for infringement for failing to adequately plead inducement, and more specifically for failing to adequately allege acts that constitute active inducement of the asserted patents. According to the district court, the warnings of side effects in appellee’s label did not recommend, encourage or promote infringement. Likewise, the press releases, while potentially evidence of intent, did not plausibly evidence an inducing act

On appeal, the Federal Circuit disagreed. The Federal Circuit took issue with the district court’s evaluation of the allegations, holding that on a motion to dismiss where the generic product is already approved (i.e., not your typical Hatch-Waxman case), the evidence must be viewed in its totality, not piecemeal as the district court had done. The Federal Circuit explained that this was not a typical “skinny label” case where the allegations are based solely on the label. Instead, the evidence here encompassed the combination of the label, public statements, and marketing materials, including public statements that provide usage information and sales data about the cardiovascular risk indication. Here, the appellee did not merely market its drug as a generic or merely skinny label around an indication, it did much more. Thus, based on the totality of the material cited in the complaint, the Federal Circuit held it is plausible that a physician could discern an encouragement to use the generic Vascepa for indications other than SH. 

Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., Case No. 2023-1169 (Fed. Cir. Jun. 25, 2023)

Share This Insight

Previous Entries

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to invalidate claims in district court.

...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.

...

Read More

IP Newsflash

April 1, 2025

The District of Delaware recently denied in part a motion to compel production of documents and testimony between a patentee and potential investors, valuation firms and an international bank based on the common interest exception. In so doing, the court reaffirmed that disclosure of privileged information to third parties will generally waive privilege unless it can be shown that the parties’ interests are identical and the communications are legal, not solely commercial.

...

Read More

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.